HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow's latest quarterly earnings call on November 12, 2026, provided investors with valuable insights into the company's growth trajectory. Revenue expanded 57% year over year in Q3 2026, reaching $72.9 million, as adoption of the AI diagnostic platform surged across cardiovascular care pathways. Notable factors driving this growth included increased utilization of FFRct and Plaque Analysis, both contributing to an impressive 83.8% non-GAAP gross margin.

Clinical trial data revealed that Plaque Analysis led to a 34% reduction in major cardiovascular disease events for 6,000 patients compared to CCTA scans alone. This evidence, coupled with the company's plans to initiate three clinical trials in late 2026 and early 2027, could unlock an additional $6 billion market and expand the total addressable market to $11 billion. Management expects to begin reporting data by the end of 2028 and enter these new markets before the end of the decade.

Operational leverage appears to be strengthening as revenue growth outpaces expenses, leading to significant narrowing of operating losses. With $253 million in cash and short-term investments, HeartFlow expects to maintain operations until achieving positive cash flow. Competitive advantages in proprietary imaging software, growing clinical trial evidence, and expanding health plan coverage ensure HeartFlow's long-term position in the market.

The company remains committed to its midterm non-GAAP gross margin target of 85%, with confidence in achieving cash flow profitability by mid-2028.